

BARD (C.R.), INC. NYSE-BCR

RECENT PRICE **81.84** P/E RATIO **15.2** (Trailing: 16.7 Median: 21.0) RELATIVE P/E RATIO **0.90** DIV'D YLD **0.8%** **VALUE LINE**

TIMELINESS 3 Lowered 6/26/09
SAFETY 1 Raised 12/1/06
TECHNICAL 3 Raised 10/30/09
BETA .55 (1.00 = Market)


High: 25.1 29.9 27.5 32.5 32.0 40.8 65.1 72.8 85.7 95.3 101.6 88.4
 Low: 14.3 20.8 17.5 20.4 22.0 27.0 40.1 60.8 59.9 76.6 70.0 68.9

LEGENDS
 — 16.0 x "Cash Flow" p sh
 ... Relative Price Strength
 2-for-1 split 6/04
 Options: Yes
 Shaded area: prior recession
 Latest recession began 12/07

2012-14 PROJECTIONS
 Ann'l Total
 Price Gain Return
 High 155 (+90%) 18%
 Low 125 (+55%) 12%

Insider Decisions
 J F M A M J J A S
 to Buy 0 0 0 0 0 0 0 0 0
 Options 1 3 1 2 3 1 1 1 1
 to Sell 1 3 1 3 3 1 1 4 2

Institutional Decisions
 4Q2008 1Q2009 2Q2009
 to Buy 243 212 229
 to Sell 207 241 252
 Hld's(000) 85733 85122 86717



1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	© VALUE LINE PUB., INC.	12-14
9.32	9.78	9.96	10.48	10.69	11.31	10.21	10.79	11.28	12.34	13.85	15.82	17.03	19.25	21.98	24.67	26.60	31.90	Sales per sh	42.80
1.15	1.26	1.32	1.41	1.35	1.50	1.64	1.72	1.87	2.12	2.40	3.03	3.76	4.14	4.85	5.50	6.15	7.00	"Cash Flow" per sh	9.40
.80	.89	.89	.91	.83	.86	1.14	1.23	1.38	1.68	1.94	2.45	3.03	3.29	3.84	4.44	5.05	5.75	Earnings per sh ^A	7.80
.27	.29	.31	.33	.35	.37	.39	.41	.42	.43	.45	.47	.50	.54	.58	.62	.68	.76	Div'ds Decl'd per sh ^B	.94
.29	.33	.35	.37	.29	.43	.26	.19	.26	.40	.70	.71	.93	.68	.51	.70	.70	.85	Cap'l Spending per sh	1.20
3.68	4.23	4.94	5.28	5.05	5.51	5.65	6.03	7.53	8.53	10.10	12.99	14.77	16.46	18.44	19.89	19.55	22.90	Book Value per sh ^C	39.25
104.20	104.10	114.20	113.97	113.57	103.00	101.56	101.82	104.77	103.21	103.51	104.67	104.01	103.16	100.19	99.39	95.00	92.50	Common Shs Outst'g ^D	90.00
16.2	14.5	16.3	17.6	19.0	22.2	22.2	18.4	18.9	16.4	17.6	21.9	22.0	22.3	21.7	20.5	20.5	20.5	Avg Ann'l P/E Ratio	18.0
.96	.95	1.09	1.10	1.10	1.15	1.27	1.20	.97	.90	1.00	1.16	1.17	1.20	1.15	1.23	1.23	1.23	Relative P/E Ratio	1.20
2.1%	2.3%	2.1%	2.1%	2.2%	1.9%	1.5%	1.8%	1.6%	1.6%	1.3%	.9%	.7%	.7%	.7%	.7%	.7%	.7%	Avg Ann'l Div'd Yield	.7%

CAPITAL STRUCTURE as of 9/30/09
 Total Debt \$149.8 mill. Due in 5 Yrs None
 LT Debt \$149.8 mill. LT Interest \$10.1 mill.
 (6% of Cap'l)

Leases, Uncapitalized Annual Rentals \$21.2 mill.

Pension Assets-12/08 \$181.0 mill. **Oblig.** \$284.1 mill.

Pfd Stock None

Common Stock 96,536,202 shares
MARKET CAP: \$7.9 billion (Large Cap)

1036.5	1098.8	1181.3	1273.8	1433.1	1656.1	1771.3	1985.5	2202.0	2452.1	2525	2950	Sales (\$mill)	3850
23.9%	22.2%	22.6%	23.1%	23.2%	25.2%	28.4%	27.7%	28.9%	30.0%	30.4%	29.0%	Operating Margin	29.0%
49.1	49.6	53.2	42.3	44.7	54.7	63.8	74.9	80.0	90.9	91.5	93.5	Depreciation (\$mill)	115
117.6	125.3	143.2	176.9	204.0	262.7	327.4	351.8	406.4	455.4	495	555	Net Profit (\$mill)	735
31.9%	30.2%	30.1%	28.1%	27.5%	26.5%	26.0%	27.5%	29.6%	28.9%	27.0%	27.0%	Income Tax Rate	27.0%
11.3%	11.4%	12.1%	13.9%	14.2%	15.9%	18.5%	17.7%	18.5%	18.6%	19.6%	18.8%	Net Profit Margin	19.0%
176.6	302.1	412.9	441.1	453.2	663.7	623.5	838.0	960.3	1081.1	890	1060	Working Cap'l (\$mill)	1390
158.4	204.3	156.4	152.2	151.5	151.4	.8	150.6	149.8	149.8	150	150	Long-Term Debt (\$mill)	150
574.3	613.9	788.7	880.4	1045.7	1360.1	1536.1	1698.0	1848.0	1977.2	1855	2115	Shr. Equity (\$mill)	3530
16.8%	16.5%	15.9%	17.7%	17.6%	17.8%	21.7%	19.5%	20.6%	21.7%	25.0%	24.5%	Return on Total Cap'l	20.0%
20.5%	20.4%	18.2%	20.1%	19.5%	19.3%	21.3%	20.7%	22.0%	23.0%	26.5%	26.0%	Return on Shr. Equity	21.0%
13.5%	13.6%	12.7%	15.0%	15.0%	15.7%	17.9%	17.4%	18.7%	19.9%	23.0%	23.0%	Retained to Com Eq	18.5%
34%	33%	30%	25%	23%	19%	16%	16%	15%	14%	13%	13%	All Div'ds to Net Prof	12%

CURRENT POSITION

(\$MILL.)	2007	2008	9/30/09
Cash Assets	570.6	592.1	632.1
Receivables	362.0	394.1	415.8
Inventory (LIFO)	244.7	275.1	311.1
Other	64.7	92.9	95.4
Current Assets	1242.0	1354.2	1454.4
Accts Payable	50.2	53.5	56.1
Debt Due	.8	--	--
Other	230.7	219.6	191.1
Current Liab.	281.7	273.1	247.2

ANNUAL RATES

Past 10 Yrs.	Past 5 Yrs.	Est'd '06-'08	'06-'08
of change (per sh)	10 Yrs.	5 Yrs.	to '12-'14
Sales	7.5%	12.0%	12.0%
"Cash Flow"	13.0%	17.5%	11.5%
Earnings	16.0%	18.5%	12.5%
Dividends	5.0%	6.0%	8.5%
Book Value	13.0%	16.0%	13.5%

QUARTERLY SALES (\$ mill.)

Cal-endar	Mar.31	Jun.30	Sep.30	Dec.31	Full Year
2006	467.5	498.2	498.9	520.9	1985.5
2007	528.2	545.7	544.8	583.3	2202.0
2008	584.0	617.1	616.8	634.2	2452.1
2009	596.4	624.6	637.0	667	2525
2010	700	730	750	770	2950

EARNINGS PER SHARE ^A

Cal-endar	Mar.31	Jun.30	Sep.30	Dec.31	Full Year
2006	.82	.81	.79	.87	3.29
2007	.95	.91	.96	1.02	3.84
2008	1.06	1.10	1.10	1.19	4.44
2009	1.17	1.23	1.31	1.34	5.05
2010	1.35	1.40	1.46	1.54	5.75

QUARTERLY DIVIDENDS PAID ^B

Cal-endar	Mar.31	Jun.30	Sep.30	Dec.31	Full Year
2005	.12	.12	.13	.13	.50
2006	.13	.13	.14	.14	.54
2007	.14	.14	.15	.15	.58
2008	.15	.15	.16	.16	.62
2009	.16	.16	.17	.17	.66

BUSINESS: C.R. Bard, Inc. has four core segments: Vascular (26% of '08 sales): angioplasty & angiography catheters, stents, vasc. grafts & blood oxygenators. Urology (29%): *Foley* catheters, urine collection sys. & incontinence aids. Oncology (26%): specialty access catheters & ports, gastroenterological pdts. & bladder & prostate cancer tests. Surgical Specialties (15%): hernia repair

C.R. Bard's third-quarter earnings bested our estimate by a nickel a share. The bottom-line result of \$1.31 was 19% higher than the year-earlier tally. Indeed, the company continues to perform well, as the top line rose at all four of Bard's primary operating divisions. Wider margins propelled the bottom line, while also allowing for a 23% increase in research and development expense. This should help Bard develop new, innovative products to keep the top and bottom lines on an upward trajectory. For the full year, we've upped our share-net estimate by a dime, to \$5.05, to reflect the better-than-expected September-period result and a \$0.05 increase in our fourth-quarter call. This would represent a roughly 14% advance from 2008's tally.

We look for the bottom line to rise at a similar pace next year. Bard will be facing easy top-line comparisons, since 2009 has been a challenging year. Indeed, the deep economic malaise trickled down to the recession-resistant healthcare industry. However, patients will continue needing medical treatment regardless of economic conditions, so Bard's customers

pdts. & orthopedic & laparoscopic irrigation pdts. "Other" (4%): deemphasized pdts. Int'l, 32.2% of total, R&D, 8.1%. '08 depr. rate: 15.8%. Has 11,000 empls. Off. and dir. own 3.1% of stk.; Capital World Investors, 10.5%; FMR Corp., 9.4% (3/09 Proxy). Chrmn. & CEO: Timothy M. Ring. Inc.: NJ. Addr.: 730 Central Ave, Murray Hill, NJ 07974. Tel.: 908-277-8000. Web: www.crbard.com.

will need to stock up on supplies. Thus, we expect a 15%-20% advance on the top line, to nearly \$3.0 billion, resulting in a 14% bottom-line climb, to \$5.75 a share.

This neutrally ranked stock offers solid 3- to 5-year appreciation potential. Because of the post-World War II "baby boom", a healthy percentage of the U.S. population will reach senior-citizen age in the next few years. Since these individuals require more healthcare services than the average adult, demand for Bard's products should rise not only over the pull to 2012-2014, but beyond that period as well. What's more, the company has done a good job of bringing successful products to the market. Considering these factors, we think the stock's long-term capital growth potential exceeds the *Value Line* median. Further, these shares carry our Highest (1) rank for Safety and the company's Financial Strength rating is excellent. What's more, Bard's ratings for Stock Price Stability, Price Growth Persistence, and Earnings Predictability are all top-notch. All told, we see an excellent risk-reward scenario here.

Tom Nikic, CFA November 27, 2009

(A) Based on avg. shrs. outstanding until '96, dil. thereafter. Excl. net nonrecr.: '93, d27c; '94, d17c; '95, d12c; '96, d10c; '97, d20c; '98, \$1.40; '99, 1c; '00, d18c; '02, d21c; '03, d34c; '04, 37c; '05, 9c; '06, d74c; '08, d38c; '09, Q1, d7c; Q2, d12c. Incl. one-time gain from add'l month of acct'g. for fgn. operations: '98, 2c. Qtrly egs. may not sum due to rounding. Next egs. rpt. due late Jan. (B) Dividends historically paid in early Feb., May, Aug., and Nov. ■ Div'd reinv. plan avail. (C) Incl. intang. In '08: \$822.4 mill., \$827/sh. (D) In mill., adj. for split.

© 2009, Value Line Publishing, Inc. All rights reserved. Factual material is obtained from sources believed to be reliable and is provided without warranties of any kind. THE PUBLISHER IS NOT RESPONSIBLE FOR ANY ERRORS OR OMISSIONS HEREIN. This publication is strictly for subscriber's own, non-commercial, internal use. No part of it may be reproduced, resold, stored or transmitted in any printed, electronic or other form, or used for generating or marketing any printed or electronic publication, service or product.

Company's Financial Strength	A++
Stock's Price Stability	100
Price Growth Persistence	100
Earnings Predictability	100

To subscribe call 1-800-833-0046.